Paclitaxel polymeric micelle formulation - Samyang

Drug Profile

Paclitaxel polymeric micelle formulation - Samyang

Alternative Names: Cremophor EL-free polymeric micelle of paclitaxel; Cynviloq; Genexol-PM; Genexsol; IG-001; NANT-008; Nant-paclitaxel; paclitaxel loaded polymeric micelle - Samyang

Latest Information Update: 17 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Boryung Pharmaceutical; NantPharma; Samyang Biopharmaceuticals Corporation; Samyang Group; Sorrento Therapeutics
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II Bladder cancer; Pancreatic cancer
  • Phase I/II Gastric cancer
  • Phase I Gynaecological cancer

Most Recent Events

  • 30 Jul 2018 Phase-I/II clinical trials in Gastric cancer (Late-stage disease) in South Korea (Intraperitoneal) (NCT03618758)
  • 27 Feb 2018 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in USA (IV) (NCT03127124)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Bulgaria (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top